Biphasic effects of anandamide

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 2, 1998, Pages 347-352

  Sulcova, E ^a   Mechoulam, R ^b   Fride, E ^b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Agonistic behavior; Anandamide; Biphasic effects; Cannabinoids; Catalepsy; Open field; Phagocytosis

Indexed keywords

ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND;

AGGRESSION; ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CATALEPSY; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HYPOTHERMIA; LEUKOCYTE; LOCOMOTION; MOUSE; PHAGOCYTOSIS; PRIORITY JOURNAL;

AGGRESSION; ANIMALS; ARACHIDONIC ACIDS; CALCIUM CHANNEL BLOCKERS; CANNABINOIDS; CATALEPSY; CHEMILUMINESCENT MEASUREMENTS; DEFECATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LEUKOCYTES; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MOTOR ACTIVITY; PAIN MEASUREMENT; PHAGOCYTOSIS; POLYUNSATURATED ALKAMIDES;

EID: 0032005722     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00422-X     Document Type: Article

References (50)

1. Ankier S. I. New hot plate tests to quantify antinocoception and narcotic antagonist activities. Eur. J. Pharmacol. 27:1974;1-4.
2. Bouabala M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., Le Fur G., Casellas P. Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214:1993;173-180.
3. 9-tetrahydrocannabinol on learning. Soc. Neurosci. Abstr. 21:1995;726.
4. Crain S. M., Shen K. F. Opioids can evoke direct receptor mediated excitatory effects on sensory neurons. Trends Pharmacol. Sci. 11:1990;77-81.
5. Crawley J. N., Corwin R. L., Robinson J. K., Felder C. C., Devane W. A., Axelrod J. Anandamide, and endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav. 46:1993;967-972.
6. Cruciani R. A., Dvorkin B., Morris S. A., Crain S. M., Makman M. H. Direct coupling of opoid receptors to both stimulatory and inhibitory guanine-sensory neuron hybrid cells. Proc. Natl. Acad. Sci. USA. 90:1993;3019-3023.
7. Davis W. M., Moreton J. E., King W. T., Pace H. B. Marihuana on locomotor activity. Biphasic effect and tolerance development Res. Commun. Chem. Pathol. Pharmacol. 3:1972;29-35.
8. Derocq J. M., Sequi M., Marhand J., Lefur G., Casellas P. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett. 369:1995;177-182.
9. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
10. Dewey W. L. Cannabinoid pharmacology. Pharmacol. Rev. 38:1986;151-178.
11. Eddy N. B., Fuhrmeister Touchberry C., Lieberman J. E. Synthetic analgesics. I. Methadon isomers and derivatives. J. Pharmacol. 98:1953;121-137.
12. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S. D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 92:1995;3376-3380.
13. Felder C. C., Briley E. M., Axelrod J., Simpson J. T., Mackie K., Devane W. A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 90:1993;7656-7660.
14. Fride E. Anandamides. Tolerance and cross-tolerance to delta 9-tetrahydrocannabinol Brain Res. 697:1995;83-90.
15. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;313-314.
16. 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 272:1995;699-707.
17. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:1995;54-61.
18. Gilman A. G. G-proteins and dual control of adenylate cyclase. Cell. 36:1984;577-579.
19. Grant E. C., Mackintosh J. H. Comparison of the social postures of some laboratory rodents. Behaviour. 21:1963;246-259.
20. Howlett A. C., Qualy J. M., Khachatrian L. L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29:1986;307-313.
21. Jarv J., Toomela T., Karelson E. Dual effect of carbachol on the muscarinic receptor. Biochem. Mol. Biol. Int. 30:1993;649-654.
22. Kellnerova R., Sulcova A., Strnadova V. Psychoneuroimmunological effects of interleukin-2, diazepam and their interactions. Homeostasis. 36:1995;45-47.
23. Kellnerova R., Sulcova A., Strnadova V. Behavioural and immune response to interferon-alfa, diazepam and their interactions. Homeostasis. 37:1996;140-141.
24. Krsiak M. Timid single-housed mice. Their value in prediction of psychotropic activity of drugs Br. J. Pharmacol. 55:1975;141-150.
25. Lee M., Yang K. H., Kaminski N. E. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J. Pharmacol. Exp. Ther. 275:1995;529-536.
26. Martin B. R., Compton D. R., Thomas B. F., Prescott W. R., Little P. J., Razdan R. K., Johnson M. R., Melvin L. S., Mechoulam R., Ward S. J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40:1991;471-478.
27. Mechoulam R., Fride E. The unpaved road to the endogenous cannabinoid ligand anandamide. Pertwee R. Cannabinoid receptors. 1995;Academic Press, London.
28. Mechoulam R., Hanus L., Martin B. R. Search for endogenous ligands of the cannabinoid receptor. Biochem. Pharmacol. 48:1994;1537-1544.
29. Miczek K. A. Delta-9-tetrahydrocannabinol. Antiaggressive effects in mice, rats, and squirrel monkeys Science. 199:1978;1459-1461.
30. Munro S., Thomas K. L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
31. Oz M., Podrasky E., Ravindran A., Singhal S., Zhang L., Weight F. F. The endogenous cannabinoid, potently inhibits the function of nicotinic a7 receptors expressed in Xenopus oocytes. SN. 22:1996;1522.
32. Paton W. D. M., Pertwee R. G. The pharmacology of cannabis in man. Marijana. Chemistry, pharmacology, metabolism and clinical effects:1973;287-333 Academic Press, New York.
33. Pertwee R. G. Ring test. A quantitative method for assessing the "cataleptic" effect of Cannabis in mice Br. J. Pharmacol. 46:1972;753-763.
34. Randall M. D., Alexander S. P. H., Bennett T., Boyd E. A., Fry J. R., Gardiner S. M., Kemp P. A., McColloch A. I., Kendall D. A. An endogenous cannabinoid as an endothelium derived vasorelaxant. Biochem. Biophys. Res. Commun. 229:1996;114.
35. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J. C., Le Fur G. SR14171A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
36. 37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 276:1996;56-63.
37. Rovati G. E., Nicosia S. Lower efficacy. Interaction with an inhibitory receptor or partial agonism? Trends Pharmacol. Sci. 15:1994;140-144.
38. Schwarz H., Blanco F. J., Lotz M. Anandamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J. Neuroimmunol. 55:1994;107-115.
39. Siegel S. Nonparametric statistics for the behavioral sciences. 1956;McGraw-Hill, New York.
40. Smith P. B., Compton D. R., Welch S. P., Razdan R. K., Mechoulam R., Martin B. R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
41. Steele R. W. Clinical applications of chemiluminescence of granulocytes. Rev. Infect. Dis. 13:1991;918-925.
42. Szabadi E. A model of two functionally antagonistic receptor populations activated by the same agonist. J. Theor. Biol. 69:1977;101-112.
43. Tono-Oka T., Ueno N., Matsumoto T., Ohkawa M., Matsumoto S. Chemiluminescence of whole blood. Clin. Immunol. Immunopathol. 26:1983;66-75.
44. Turkanis S. A., Karler R. Excitatory and depressant effects of delta 9-tetrahydrocannabinol and cannabidiol on cortical evoked responses in the conscious rat. Psychopharmacology (Berlin). 75:1981;294-298.
45. Varga K., Lake K., Martin B. R., Kunos G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol. 278:1995;279-283.
46. Venance L., Piomelli D., Glowinski J., Giaume C. Inhibition by anandamide of gap junctions and intercellular calcium in striatal astrocytes. Nature. 376:1995;590-594.
47. Vial T., Tedone R., Patriarca C., Descotes J. Effect of serotonin on the chemiluminescence response of rat peripheral blood leukocytes. Int. J. Immunopharmacol. 17:1995;813-819.
48. Vogel Z., Barg J., Levy R., Saya D., Heldman E., Mechoulam R. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61:1993;352-355.
49. Weeks I., Sturgess M. L., Woodhead J. S. Chemiluminescence immunoassay. an overview Clin. Sci. 70:1986;403-408.
50. 9-tetrahydrocannabinol on circling in rats induced by intranigral muscimol administration. Eur. J. Pharmacol. 282:1995;251-254.